Atrial Natriuretic Peptide IDs Left Atrial Reverse Remodeling
Finding among patients with atrial fibrillation undergoing catheter ablation
FRIDAY, March 25, 2016 (HealthDay News) -- Preprocedural serum atrial natriuretic peptide (ANP) levels predict left atrial reverse remodeling after catheter ablation in patients with atrial fibrillation (AF), according to a study published online March 23 in JACC: Clinical Electrophysiology.
Koki Nakanishi, M.D., from Baba Memorial Hospital in Sakai, Japan, and colleagues assessed 104 consecutive patients undergoing radiofrequency catheter ablation (RFCA) for AF. All patients underwent multidetector computed tomography examination and laboratory tests (ANP, plasma B-type natriuretic peptide [BNP], and high-sensitivity C-reactive protein [hs-CRP]) before and six months after RFCA. Patients exhibiting a ≥15 percent decrease in the left atrial volume index were defined as responders.
The researchers found that 49 patients (47 percent) were classified as responders at follow up. Serum ANP and BNP levels were significantly higher in the responders before the procedure, compared to the nonresponders (both P < 0.01). Responders also had a significant decrease in the log ANP, log BNP, and log hs-CRP levels from baseline to follow-up (all P < 0.01). Log ANP level before RFCA and maintenance of sinus rhythm during follow-up were independent predictors of left atrial reverse remodeling (both P < 0.01).
"In this study, 47 percent of the patients exhibited left atrial reverse remodeling after RFCA for AF, with a concomitant improvement in serum ANP, BNP, and hs-CRP levels," the authors write.